Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoadjuvant Operable Breast Cancer × Cyclophosphamide × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 467 Triple Negative Breast Neoplasms 73 Inflammatory Breast Neoplasms 29 Breast Neoplasms, Male 26 Neoplasm Metastasis 23 Carcinoma, Non-Small-Cell Lung 21 Ovarian Neoplasms 20 Melanoma 20 Pancreatic Neoplasms 13 Neoplasms 13 Colorectal Neoplasms 12 Stomach Neoplasms 10 Carcinoma, Renal Cell 10 Multiple Myeloma 9 Lung Neoplasms 9 Carcinoma, Ovarian Epithelial 9 Carcinoma, Hepatocellular 8 Lymphoma, Non-Hodgkin 7 Sarcoma 6 Neutropenia 6 Lymphoma, Follicular 6 Lymphoma 6 Colonic Neoplasms 6 Carcinoma, Ductal, Breast 6 Small Cell Lung Carcinoma 5 Recurrence 5 Neuroblastoma 5 Lymphoma, Mantle-Cell 5 Lymphoma, Large-Cell, Immunoblastic 5 Lymphoma, Large B-Cell, Diffuse 5

Interventions

palbociclib 1 Letrozole 1 Fluorouracil 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02400567 2022-03-15

NeoPAL

UNICANCER

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡